These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29309621)

  • 1. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease-authors' response.
    Sperandio da Silva GM; Mediano MFF; Hasslocher-Moreno AM; Holanda MT; Sousa AS; Sangenis LHC; Cubides JC; Saraiva RM
    J Antimicrob Chemother; 2018 Apr; 73(4):1115-1116. PubMed ID: 29309621
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.
    Novaes RD; Gonçalves RV
    J Antimicrob Chemother; 2018 Apr; 73(4):1114-1115. PubMed ID: 29253162
    [No Abstract]   [Full Text] [Related]  

  • 3. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.
    Sperandio da Silva GM; Mediano MFF; Hasslocher-Moreno AM; Holanda MT; Silvestre de Sousa A; Sangenis LHC; Brasil PEAAD; Mejía RA; Fux CP; Cubides JC; Saraiva RM; Brum-Soares LM
    J Antimicrob Chemother; 2017 Sep; 72(9):2596-2601. PubMed ID: 28645201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe invalidating pain syndrome associated with benznidazole therapy for Chagas' disease.
    Moll C; Peris P; Moreno A; Muñoz J; Guañabens N
    Clin Rheumatol; 2008 Feb; 27(2):269-70. PubMed ID: 17703333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America.
    Pinheiro E; Brum-Soares L; Reis R; Cubides JC
    Rev Soc Bras Med Trop; 2017; 50(3):296-300. PubMed ID: 28700045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "We have already heard that the treatment doesn't do anything, so why should we take it?": A mixed method perspective on Chagas disease knowledge, attitudes, prevention, and treatment behaviour in the Bolivian Chaco.
    Parisi S; Navarro M; Du Plessis JD; Shock JP; Apodaca Michel B; Lucuy Espinoza M; Terán C; Calizaya Tapia NA; Oltmanns K; Baptista Mora A; Saveedra Irala C; Rivera Rojas AA; Rubilar G; Zoller T; Pritsch M
    PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008752. PubMed ID: 33119632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose benznidazole in a 62-year-old Bolivian kidney transplant recipient with Chagas central nervous system involvement.
    Montero M; Mir M; Sulleiro E; Avalos Esquivel JL; García López E; Molina-Morant D; López Montesinos I; Sorlí L; Veliz Espinosa G; Mounteis Oliva E; Crespo M; Monge I; Horcajada JP; Grau S; Pascual J
    Int J Infect Dis; 2019 Jan; 78():103-106. PubMed ID: 30391324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease.
    Laucella SA; Segura EL; Riarte A; Sosa ES
    Clin Exp Immunol; 1999 Dec; 118(3):423-7. PubMed ID: 10594562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras.
    Escribà JM; Ponce E; Romero Ade D; Viñas PA; Marchiol A; Bassets G; Palma PP; Lima MA; Zúniga C; Ponce C
    Mem Inst Oswaldo Cruz; 2009 Nov; 104(7):986-91. PubMed ID: 20027465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail.
    Crespillo-Andújar C; Chamorro-Tojeiro S; Norman F; Monge-Maillo B; López-Vélez R; Pérez-Molina JA
    Clin Microbiol Infect; 2018 Dec; 24(12):1344.e1-1344.e4. PubMed ID: 29906591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should benznidazole be used in chronic Chagas' disease?
    Bestetti RB
    Lancet; 1997 Mar; 349(9052):653. PubMed ID: 9057760
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
    Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.
    Pereira-Chioccola VL; Fragata-Filho AA; Levy AM; Rodrigues MM; Schenkman S
    Clin Diagn Lab Immunol; 2003 Sep; 10(5):826-30. PubMed ID: 12965912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The third and new face of Chagas disease].
    Pays JF
    Bull Soc Pathol Exot; 2016 Aug; 109(3):139-42. PubMed ID: 27376642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
    Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posaconazole versus benznidazole for chronic Chagas' disease.
    Molina I; Salvador F; Sánchez-Montalvá A
    N Engl J Med; 2014 Sep; 371(10):966. PubMed ID: 25184871
    [No Abstract]   [Full Text] [Related]  

  • 19. Posaconazole versus benznidazole for chronic Chagas' disease.
    Rassi A; Rassi A; Marin-Neto JA
    N Engl J Med; 2014 Sep; 371(10):965. PubMed ID: 25184872
    [No Abstract]   [Full Text] [Related]  

  • 20. Posaconazole versus benznidazole for chronic Chagas' disease.
    Bestetti RB; Restini CB
    N Engl J Med; 2014 Sep; 371(10):966. PubMed ID: 25184873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.